A study evaluating SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA)

Trial Profile

A study evaluating SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA)

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs SBP 101 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2017 Planned initiation date changed to 1 Jan 2018.
    • 14 Nov 2017 According to a Sun BioPharma media release, enrollment is expected to begin in first quarter of 2018.
    • 05 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top